Pei Guo
Shanghai, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Extracellular Ubiquitin Drives M2 Macrophage Polarization in Multiple Myeloma Through JAK1/STAT3-mediated Transcriptional Activation of CXCR4.
Journal: Journal of cellular biochemistry
Published: May 30, 2025
GPRC5D-targeted CAR T-cell therapy (CT071) in patients with relapsed or refractory multiple myeloma: a first-in-human, single-centre, single-arm, phase 1 trial.
Journal: The Lancet. Haematology
Published: March 15, 2025
Analysis of efficacy and safety of BCMA chimeric antigen receptor T cells in the treatment of 5 patients with recurrent/refractory IgD multiple myeloma
Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
Published: March 19, 2024
Elevated serum levels of soluble B-cell maturation antigen as a prognostic biomarker for multiple myeloma.
Journal: Clinical and experimental immunology
Published: October 04, 2023
The efficacy and safety analysis of pomalidomide in the treatment of relapsed/refractory multiple myeloma
Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
Published: March 29, 2023
A case-control study of multiple myeloma patients with central nervous system involvement
Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
Published: January 28, 2023
The efficacy and safety of daratumumab in relapsed and refractory multiple myeloma
Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
Published: March 07, 2021
Dysregulated circular RNAs are closely linked to multiple myeloma prognosis, with circ_0026652 predicting bortezomib‑based treatment response and survival via the microRNA‑608‑mediated Wnt/β‑catenin pathway.
Journal: Oncology reports
Published: January 05, 2021
Showing 1-9 of 9
Last Updated: 09/26/2026